Serina Therapeutics has developed a new way of synthesizing polyoxazoline (POZ) polymers for drug delivery applications that, it claims, is free of the drawbacks that have hampered previous production methods.
SAFC, the custom manufacturing and business services wing of Sigma Aldritch, has announced a licensing agreement with biotech company, Agilent Technologies, for the sale of its nucleic acids synthesis products and technologies.
Alkermes saw losses increase in fiscal 2011 but has issued an upbeat outlook on higher revenues, portfolio expansion and impending acquisition of Elan Drug Technologies (EDT).
Californian biotech tool manufacturer Life Technologies has teamed with German contract research organisation (CRO) ProBiogen to release a range of royalty-free Gibco Freedom Cell Line Development Kits.
Chemicals supplier Aceto Corp has its sights set on opportunities in the generic drug sector after soaring active pharmaceutical ingredient (API) and intermediates sales helped it to a strong set of quarterly financials.
Merck South Africa, a subsidiary of German pharma giant, Merck KGaA, has sold its Merck Pharmaceutical Manufacturing (MPM) operations in Johannesburg to investment firm, Nkunzi Investment Holdings.
Albany Molecular Research (AMRI) posted a modest net loss on costs and restructuring charges, but saw revenue grow considerably in the first quarter thanks to contracting business and royalties.
Non-profit epilepsy research sponsor, Epilepsy Therapy Project (ETP), has announced it is to invest in central nervous system (CNS) drug delivery specialist, ICVrx, to support the development of novel drug tech designed to tackle refractory epilepsy.
The second draft of Excipact, a set of certification standards for drug excipient producers being developed by the EFCG, FECC, IPEC and PQD, has been sent to industry stakeholders for consultation.
US drug developer, PharmStar Pharmaceuticals, has reached an agreement to buy a new 24,000 square foot manufacturing facility in Wilson, North Carolina.
Pharma giant Eli Lilly and medical device maker Medtronic are to collaborate on the research and development of an implantable drug delivery system for the treatment of Parkinson’s disease.
The United States Pharmacopeial Convention (USP) and the Chinese Pharmacopoeia Commission (ChP) have made mutual executive appointments in an effort to further align drug quality standards.
Gilead has entered into a licence and collaboration agreement with drug delivery specialists MicroDose Therapeutx to develop a treatment for respiratory syncytial virus (RSV).
US-based tissue regeneration specialist, Organogensis, has broken ground on the construction of the world’s largest automated living cell manufacturing plant in Canton, Massachusetts.
Univar has announced plans to ramp up capacity for medicinal white oils, predicting that increased regulatory focus on supply chain integrity will drive drug industry demand.
Nano Terra, a surface engineering and nanotechnology company based in Brighton Massachusetts, US, has struck a deal to acquire neighbouring drug developer, Surface Logix.
Bend Research, the Oregon US-based drug manufacturer, has received a new US patent covering the use of polymer additives to help increase the efficacy of low-solubility drugs.
Pharmaceutical giant Pfizer has agreed to sell Capsugel, its drug delivery technology unit, to US investment group Kohlberg Kravis Roberts & Co (KKR) for $2.4bn (€1.7bn).
Chinese (API) maker ScinoPharm said that it met its sales targets in 2010, despite rocketing raw materials prices, cutbacks in government healthcare spending in key markets and currency revaluation.
Scientists from the University of Syracuse’s chemistry department have created a new drug delivery system which they claim will improve the efficacy of cancer-killing drugs.
Cytovance Biologics, the US-based biopharmaceutical contract manufacturer (CMO), has secured a growth equity investment from Connecticut, US-based private investors, Great Point Partners.
Researchers have uncovered a link between exposure to sunlight and the body's ability to break down medicines that could have big implications for formulators.
Swiss pharmaceutical ingredient maker Helsinn says its new cytotoxic API production plant will be operational for laboratory-scale projects early next year.
